YOU ARE HERE:
Changing treatments news
page  of 6
 
Headline
Date
  Etravirine (Intelence) approved in Europe for treatment-experienced patients
02.09.08
  Uptake of second-line treatment `stagnant` in developing world
14.08.08
  Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy
06.08.08
  US study confirms long-term use of AZT, d4T result in lipoatrophy
27.05.08
  Adherence predicts viral failure just as well as CD4 count change, South African study shows
20.05.08
  Does tenofovir increase the risk of efavirenz-associated liver side-effects?
09.05.08
  Dual class drug resistance present in two-thirds of South African HIV cohort on failing ART
05.05.08
  Clinical monitoring as effective as CD4 count and viral load for deciding when to switch to second-line ART in poor countries
25.04.08
  ART recommended for all with CD4 counts below 350, say South African doctors
17.04.08
  Start anti-HIV treatment with a CD4 cell count of 350 with efavirenz and Truvada, say draft British guidelines
01.04.08
  CROI: Risk of second virological failure has declined since 1996, but risk of death remains stable
07.02.08
  WHO expert panel wants fewer second-line ART choices
31.01.08
  Kaletra monotherapy studies yield conflicting results
28.01.08
  Less risk of AIDS for patients with low CD4 cell count and no treatment options who stay on failing therapy
25.01.08
  Raltegravir now available for UK patients
24.01.08
  Factors affecting HIV therapy choice in women have changed
23.01.08
  EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance
31.10.07
  EACS: Nevirapine studies highlight new first-line uses
31.10.07
  EACS: One in five UK patients remains on failing therapy for over a year
29.10.07
  Undetectable viral load is goal for all, together with earlier treatment, say new European treatment guidelines
25.10.07

page  of 6